PGx for Oncology

PGx testing helps oncology teams personalize cancer treatment by identifying genetic differences that can affect how a patient metabolizes and responds to key oncology and supportive medications.

The AccessDx PGx Profile:

  • Helps reduce serious adverse drug reactions
  • Reduces the risk of severe toxicity
  • Improves treatment tolerance
  • Enables more personalized cancer care
  • Provides actionable insights before treatment begins

Fill out this form to learn more details about PGx use in Oncology practices.

Name
By filling out this form, you agree to receive communications like newsletters, marketing or promotional materials, and other information from AccessDx Laboratory and our parent company, Aranscia®. You may opt-out of receiving communications from us by using the unsubscribe link at the bottom of all emails or contacting us directly.

PGx testing can guide dosing for some chemotherapy medications like Capecitabine, Fluorouracil, and Irinotecan, and can help identify patients who may not benefit from Tamoxifen2

Testing Offerings:

PGx Profile – Comprehensive Panel

Includes 37+ high-evidence and emerging-evidence genes, with four add-on genes available (APOE and HLA risk alleles)

PGx Profile – Focused Panel

Includes 20 high-evidence genes with actionable guidance, including HLA risk alleles

Single-gene DPYD Testing

Enables oncology care teams to identify patients with DPD deficiency prior to treatment with capecitabine (Xeloda®) or fluorouracil/5-FU to reduce the risk of serious adverse reactions

Therapeutic Areas Impacted:

Oncology
Behavioral Health
Gastroenterology

Hyperuricemia Management
Infection Management
Neurology

Pain Management
Rheumatology & Autoimmune Disorders
Urology

  1. Ronquillo JG, Lester WT Pharmacogenomic testing and prescribing patterns for patients with cancer in a large national precision medicine cohort Journal of Medical Genetics 2023;60:81-83.
  2. U.S. Food and Drug Administration. “Table of Pharmacogenetic Associations.” FDA, 26 Oct. 2022, www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations. Accessed 8 Apr. 2025.
  3. Chanfreau-Coffinier C, et al. Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users. JAMA Netw Open. 2019;2(6):e195345.
  4. Deenen, Maarten J et al. “Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 34,3 (2016): 227-34. doi:10.1200/JCO.2015.63.1325